Head of Global Clinical DevelopmentActicor BiotechParis, Ile-de-France, France
PB0364 - Glycoprotein VI-targeted antiplatelet therapy with glenzocimab is safe in patients exposed to current antithrombotic and fibrinolytic drugs.
Sunday, June 25, 202318:30 – 19:30 ET